The Globe and Mail reports in its Wednesday, Jan. 28, edition that Canaccord Genuity analyst Kenric Tyghe rates Aurora Cannabis "buy" in new coverage. The Globe's David Leeder writes in the Eye On Equities column that Mr. Tyghe set a share target of $10. Analysts on average target the shares at $5.99. Mr. Tyghe believes the Canadian cannabis market is a global benchmark for legal commercialization, with potential for growth through regulatory reform, consolidation and international expansion, despite some challenges. Mr. Tyghe says in a note: "Aurora Cannabis is a medical-first operator, the leading medical player in Canada, and a foremost player in the key international markets of Germany, Poland, Australia and the UK. The path to becoming a leader in global medical cannabis was far from linear given the enormity of the reset required to get where the company is today and the complexity of the regulatory backdrop against which it was achieved. The pivot domestically supported international expansion into the high-margin international markets where gross margins are, on average, roughly 2.5 times those of Aurora's (medically focused) Canadian business."